Mumbai: As the pricing war in India’s GLP-1 therapy market intensifies, Danish drugmaker Novo Nordisk has sharply reduced prices of its blockbuster semaglutide brands Ozempic and Wegovy to expand ...
Mumbai: Abbott has entered into a strategic collaboration with Novo Nordisk India to commercialise another brand of Novo’s blockbuster GLP-1 drug Ozempic (semaglutide). The partnership, which comes less than ...
Danish drugmaker Novo Nordisk will launch its blockbuster diabetes drug Ozempic in India this month, three sources familiar with the matter said, as it seeks to strengthen its foothold ...
CHENNAI: Danish drugs and insulin maker Novo Nordisk launched Wegovy, its latest and the much-awaited weight-loss drug -- a once‑a‑week semaglutide injection, in India today (June 24). The drug ...
Pharmaceutical giant Novo Nordisk is discontinuing the country's largest selling insulin, Human Mixtard, along with other insulins. The move could shake up the diabetes market, TOI reported. Despite it ...
Danish drug maker Novo Nordisk is gearing up to test the efficacy and safety of its new weekly insulin injection, IcoSema, in India. The company has got a go-ahead ...
Bengaluru: Danish drugmaker Novo Nordisk aims to bring its blockbuster weight-loss drug Wegovy to India in 2026, after securing regulatory approvals and ensuring it has enough supply to meet ...
New York: The monumental demand for weight-loss remedies like Novo Nordisk's Wegovy might assist as many as 10 competing merchandise with annual gross sales reaching up to $100 billion ...